MHRA Orders Boxed Suicide-Risk Warning on Antidepressants

MHRA is ordering a boxed suicide-risk warning, a new patient safety card, and a forthcoming ancillary leaflet across all 28 antidepressants licensed in the UK, after a Commission on Human Medicines review concluded that existing patient information leaflets do not communicate the risk of suicidal thoughts and behaviours — or persistent sexual dysfunction after stopping treatment — clearly enough. The review, published 15 October 2026, was prompted by patients and families who said the warnings were there on paper but hard to find and harder to act on.

What the review found

The review was carried out by an Expert Working Group reporting to the Commission on Human Medicines (CHM), MHRA’s independent scientific advisory body, and covered the 28 medicines currently licensed in the UK as antidepressants — principally SSRIs and SNRIs, the classes MHRA’s own safety guidance names specifically. The trigger was not a new signal in the underlying pharmacology; both suicide risk in younger patients and persistent sexual dysfunction after stopping treatment (sometimes called post-SSRI sexual dysfunction) are already documented in UK product information. The trigger was communication: patients and families raised concerns that the existing warnings, buried in the body text of lengthy leaflets, were not prominent or clear enough to inform a decision before starting treatment or to flag a worsening symptom once on it.

The review’s clinical-trial evidence base found a higher risk of suicidal thoughts and behaviours specifically among young adults aged 18 to 25. That finding does not change who can be prescribed an antidepressant or at what dose; it informs how the risk is flagged across the full patient population, since MHRA’s stated rationale is clarity of existing information rather than new restriction.

What changes on the page

• Boxed warning on PILs — a new box at the top of the leaflet signposting readers directly to the section on suicidal thoughts and behaviours, rather than leaving the warning to be found in running text.
• Patient safety card — a new, credit-card-sized, portable card carrying key safety messaging, intended to travel with the patient rather than sit in a drawer with the box.
• Ancillary safety leaflet — a separate document, developed with wider healthcare system partners and due in 2027, meant to support the conversation at a first appointment and to be given to patients already established on treatment, not only new starters.
• Sexual dysfunction disclosure — leaflets will more clearly address persistent sexual dysfunction that can continue after a patient stops taking the medicine, a risk the review found was poorly understood even among patients who had experienced it.

“Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions.” Dr Alison Cave, MHRA Chief Safety Officer, in the agency's 15 October 2026 announcement

The rollout clock, and what it means for sponsors

A written ministerial response dated 12 October 2026 sets out a staggered timeline rather than a single effective date. The revised PIL and the safety card are expected to be available electronically from October 2026; paper copies inside medicine packs are expected to follow within three to six months, with pharmacies given an interim option for earlier hard-copy access to the card for patients who need one before the pack-insert version arrives. The ancillary leaflet is a longer runway: it is still in development with wider healthcare system partners and is due in 2027, not this year.

For the marketing authorisation holders of all 28 affected medicines, that staggered timeline is an operational schedule, not a suggestion. Updating a PIL means new artwork, a new braille and large-print pathway where applicable, and coordination with printers and packers to land paper copies inside the three-to-six-month window without stranding existing inventory mid-transition. Producing and distributing a new safety card at scale, electronically first and then physically, is a packaging-supply-chain exercise most of these sponsors have not run before for this product category. And because the measure applies to a drug class rather than a single product, pharmacovigilance and regulatory affairs teams across UK-licensed antidepressant manufacturers are now working the same deadline in parallel — a pattern more familiar from a class-wide EU referral than from a single company's own safety signal.

Frequently asked questions

What did MHRA announce on 15 October 2026?

New measures to strengthen how two risks associated with antidepressant medicines are communicated to patients: suicidal thoughts and behaviours, and persistent sexual dysfunction that can continue after stopping treatment. The announcement follows a review by an Expert Working Group of the Commission on Human Medicines (CHM) of the 28 antidepressants licensed in the UK, prompted by patients and families who said existing patient information leaflets did not communicate these risks clearly enough.

What changes to the leaflet and packaging?

Patient information leaflets will carry a new boxed warning directing readers to the section on suicidal thoughts and behaviours, making it easier to find. A new, portable patient safety card is also being introduced, alongside a separate ancillary safety leaflet — developed with wider healthcare system partners — due in 2027.

When does this take effect?

Per a written ministerial response of 12 October 2026, the revised PIL and the safety card are expected to be available electronically from October 2026, with paper copies inside medicine packs following within three to six months; pharmacies have an interim option for earlier hard-copy access to the card. The supporting ancillary leaflet follows in 2027.

Does this restrict who can be prescribed an antidepressant?

No. MHRA says the aim is not to discourage use but to improve the prominence and clarity of warnings that already exist. The review found a higher risk of suicidal thoughts and behaviours among young adults aged 18 to 25 specifically, but the new measures apply across all age groups and all 28 reviewed medicines.